The FDA has approved Provention’s BLA for intravenous antibody TZIELD to delay stage 3 type 1 diabetes, making it the first disease-modifying drug indicated to slow disease progression.
Pfizer Inc. and its German partner BioNTech SE said their Omicron-tailored shot produced higher virus-neutralizing antibodies in older adults against the emerging subvariant BQ.1.1 than its original vaccine.
Moderna Inc. said its Omicron-tailored vaccines produced a better immune response against the BA.4/5 subvariants in a mid-to-late stage study, when given as a booster dose, compared with its original shot.
Researchers from the University of Washington have developed an investigational vaccine that can safely elicit an immune response against the HER2 protein, a key marker in breast cancer.
Vaccine maker Novavax Inc said on Tuesday its COVID-19 shot retooled against the Omicron BA.1 variant showed a strong immune response as the fourth dose and met the main goal of strain change in a late-stage study.
The early-stage study, which is being sponsored by BioNTech, aims to evaluate the combination shot’s safety, tolerability and immunogenicity, or the ability to generate immune response.
Moderna Inc. said on Wednesday its COVID-19 vaccine booster targeting the BA.1 subvariant of Omicron generated a strong immune response against that variant, with antibody levels staying high for at least three months.
A rebound of COVID-19 symptoms in some patients after taking Pfizer’s antiviral Paxlovid may be related to a robust immune response rather than a weak one, U.S. government researchers reported on Thursday.
Moderna sued Pfizer and its German partner BioNTech on Friday for patent infringement in the development of the first COVID-19 vaccine approved in the United States, alleging they copied technology that Moderna developed years before the pandemic.
UK’s Joint Committee on Vaccination and Immunisation agency will now decide how shot should be deployed. In addition Moderna anticipates Australia, Canada, and EU approvals soon.